Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boudot, C.
Right arrow Articles by Billat, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boudot, C.
Right arrow Articles by Billat, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 48, 33966-33972, November 26, 1999


Erythropoietin Induces Glycosylphosphatidylinositol Hydrolysis
POSSIBLE INVOLVEMENT OF PHOSPHOLIPASE C-gamma 2*

Cédric BoudotDagger , Emmanuelle PetitfrèreDagger , Zahra KadriDagger , Stany Chretien§, Patrick Mayeux, Bernard HayeDagger , and Claudine BillatDagger parallel

From the Dagger  Laboratoire de Biochimie, CNRS UPRES-A 6021, IFR 53 Biomolécules, UFR Sciences Exactes et Naturelles, BP 1039, Université de Reims Champagne-Ardenne, F 51687 Reims Cedex 2, the § Institut National de la Transfusion Sanguine (INTS), 6 Rue Alexandre Cabanel, F 75014 Paris, and  Institut Cochin de Génétique Moléculaire, INSERM U363, Hôpital Cochin, Université René Descartes, 27 Rue du Faubourg Saint Jacques, F 75014 Paris, France

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We showed that erythropoietin induced rapid glycosylphosphatidylinositol (GPI) hydrolysis and tyrosine phosphorylation of phospholipase C (PLC)-gamma 2 in FDC-P1 cells transfected with the wild-type erythropoietin-receptor. Erythropoietin-induced tyrosine phosphorylation of PLC-gamma 2 was time- and dose-dependent. By using FDC-P1 cells transfected with an erythropoietin receptor devoid of tyrosine residues, we showed that both effects required the tyrosine residues of intracellular domain on the erythropoietin receptor. Erythropoietin-activated PLC-gamma 2 hydrolyzed purified [3H]GPI indicating that GPI hydrolysis and PLC-gamma 2 activation under erythropoietin stimulation were correlated. Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma 2, whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects. Thus, our results suggest that erythropoietin regulates GPI hydrolysis via tyrosine phosphorylation of its receptor and PLC-gamma 2 activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Erythropoietin is essential for the survival, proliferation, and differentiation of the late erythroid progenitor cells (for review see Ref. 1). Erythropoietin exerts its action on its target cells by binding to specific cell-surface receptors (for review see Ref. 2). The erythropoietin receptor (Epo-R)1 belongs to the cytokine receptor superfamily, and its cytosolic domain lacks intrinsic kinase activity. Nevertheless, ligand binding leads to a rapid but transient tyrosine phosphorylation of cellular proteins, including the receptor itself (3-5). This phosphorylation is carried out via the activation of an associated tyrosine kinase, JAK2 (6, 7). Epo-R tyrosine phosphorylation creates binding sites for Src homology domain 2 (SH2) containing proteins such as Grb2, Shc, Stat5, phosphatidylinositol 3-kinase, SHP1, and SHP2 that relay and amplify the signals (for review see Ref. 8).

The glycosylphosphatidylinositol (GPI) molecules with the general structure lipid-phosphate-inositol glycan have been isolated from plants, bacteria, yeast, parasitic protozoa, and mammalian cells (9-11). In eukaryotic cells, GPI molecules may be attached to protein moieties thereby providing a membrane anchor. Free GPIs also exist under an uncomplexed form. Both forms of GPI have been shown to participate in signal transduction events (for review see Ref. 12). In different cellular systems GPI turnover is modulated by a variety of hormones, cytokines, and growth factors such as insulin (13, 14), insulin growth factor-I (15, 16), nerve growth factor (17, 18), interleukin-2 (19), thyroid-stimulating hormone (20), or erythropoietin in rat erythroid progenitor cells (21). Then the hydrolysis of glycosylphosphatidylinositol could be another pathway in signal transduction. GPI hydrolysis generates diacylglycerol and the polar group of the lipid, an inositol phosphoglycan (IPG) which can act as a second messenger (for review see Ref. 22).

The dependence on increased receptor phosphorylation and GPI hydrolysis after growth factor stimulation remains to be conclusively defined. However, tyrosine kinase inhibitors were shown to be able to partially block epidermal growth factor (EGF)-stimulated GPI hydrolysis (23), and hydrolysis of GPI in response to insulin is reduced in cells bearing kinase-deficient insulin receptors (24, 25).

The nature of the phospholipase C (PLC) responsible for hormone-induced GPI hydrolysis is still unknown. Mammalian GPI-PLC was partially purified from rat liver membranes (26) but has not yet been cloned. PI-PLC from Bacillus cereus was shown to facilitate the release of some PI-glycan-ethanolamine-anchored proteins as PI-PLC isolated from trypanosomes (27) and rat liver membranes (26, 28). Among eukaryote PI-PLC isoforms, only the gamma 1 and gamma 2 types contain SH2 and SH3 domains and become potential candidates for binding to phosphotyrosine residues during Epo receptor activation (29-31). Epo activation of a PLC was suggested in erythroid progenitor cells (32), and PLC-gamma 1 activation was evidenced in UT7 cells (33), but Epo activation of PLC-gamma 2 has never been described, whereas PLC-gamma 2 activation by macrophage-colony-stimulating factor has been described in FDC-P1 cells (34).

In this report, we show that erythropoietin induces a rapid and transient hydrolysis of GPI and tyrosine phosphorylation of PLC-gamma 2. Both effects require the presence of the same tyrosine residues on the intracellular domain of Epo receptor. We show that Epo-activated PLC-gamma 2 is able to hydrolyze purified [3H]GPI. Our results suggest that tyrosine Y1 (Tyr343), Y2 (Tyr401), Y7, and/or Y8 (Tyr464 and/or Tyr479) are implicated in Epo-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma 2, whereas tyrosines Y3 and/or Y4 (Tyr429 and/or Tyr431) seem to be involved in Epo-induced inhibition of GPI hydrolysis. Thus, our results strongly suggest that Epo regulates GPI hydrolysis via tyrosine phosphorylation of its receptor and PLC-gamma 2 activation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Purified recombinant human erythropoietin (specific activity of 120,000 units/mg) was from Roche Molecular Biochemicals. [1-3H]Ethan-1-ol-2-amine hydrochloride (26 Ci/mmol) and D-[6-3H]glucosamine hydrochloride (33 Ci/mmol) were from Amersham Pharmacia Biotech. Anti-PLC-gamma 2 antibodies (catalog number (Q-20) sc-407) were purchased from Santa Cruz Biotechnology, Inc. Anti-phosphotyrosine antibodies (4G10) (catalog number 17-123) and anti-JAK2 antibodies (catalog number 06-255) were from Upstate Biotechnology, Inc. ECL substrate solution was from Amersham Pharmacia Biotech. alpha -MEM, Iscove Dulbecco's medium, and fetal calf serum were from Life Technologies, Inc. All other reagents were purchased from Sigma.

Epo-R Mutants-- The intracellular domain of the murine Epo receptor contains 8 tyrosines as follows: Tyr343 (Y1), Tyr401 (Y2), Tyr429 (Y3), Tyr431 (Y4), Tyr443 (Y5), Tyr460 (Y6), Tyr464 (Y7), and Tyr479 (Y8) of the mature protein. Epo-R mutants were constructed as described previously (35). A schematic representation of Epo-R wild type (WT) and mutants is done in Fig. 1. The Y1-2F3-4Y5-8 Epo-R mutant was kindly provided by Dr. U. Klingmüller (Zentrum fur Molekulare Biologie, Universitat Heidelberg, Germany).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1.   Schematic representation of wild-type and mutated Epo receptors. The intracellular part of the WT Epo-R contains 8 tyrosine residues as follows: Y1 (Tyr343), Y2 (Tyr401), Y3 (Tyr429), Y4 (Tyr431), Y5 (Tyr443), Y6 (Tyr460), Y7 (Tyr464), and Y8 (Tyr479). F corresponds to a phenylalanine substitution; EC, extracellular.

Cell Cultures-- FDC-P1 cells were maintained in alpha -minimum essential medium (alpha -MEM) containing 10% fetal calf serum and 3% WEHI conditioned media as a source of interleukin-3. Stable transfections of murine Epo-R cDNA into FDC-P1 cells were done as described previously (35). After transfection, Epo-sensitive cells were maintained in alpha -MEM containing 10% fetal calf serum and 2 units/ml Epo.

Cell Labeling and Stimulation-- Cells were grown with 3% WEHI as source of growth factor and metabolically labeled with [3H]ethanolamine (1.5 µCi/ml) or [3H]glucosamine (5 µCi/ml) for 20 h prior to assay. Four hours before the end of this period, cells were starved of growth factor in alpha -MEM containing 1% (v/v) of fetal calf serum. Cells were then washed twice with alpha  medium, 25 mM HEPES, and aliquots of 10-20 × 106 cells were preincubated at 37 °C for 15 min before stimulation with 5 units/ml Epo for 0-30 min. Incubations were stopped with HClO4 (5% v/v). After centrifugation at 1200 × g, pellets and supernatants were stored at -20 °C before GPI and IPG quantitations.

Glycosylphosphatidylinositol (GPI) and Inositol Phosphate Glycan (IPG) Assays-- Lipids were extracted from the resultant pellets and analyzed by sequential acid/base silica gel thin layer chromatography (TLC, Silica Gel 60, Merck) as described previously (14) or by HPTLC (Silica Gel 60 aluminum-backed HPTLC plates, Merck) developed in chloroform/methanol/NH4OH/water (45:45:3.5:10, v/v). HPTLC plates were sprayed with EN3HANCE (NEN Life Science Products) and fluorographed on Kodak XAR-5 film. To quantitate incorporation of radiolabel into GPI, HPTLC plates were either scanned before fluorography on a Berthold LB 2821 automatic TLC linear analyzer, or 1-cm bands of TLC were scraped and their radioactivity content estimated by scintillation counting. IPG levels from perchlorate supernatants or from the aqueous phase obtained after GPI hydrolysis were determined by chromatography on a Dowex AG 1-X8 (200-400 mesh) column as described previously (13, 21).

Sensitivity of [3H]GPI to Nitrous Acid, PI-PLC, and PLC-gamma 2-- A sample of [3H]GPI from WT Epo-R FDC-P1 cells recovered after the basic thin layer chromatography was incubated in 25 mM sodium acetate, 0.16 M sodium nitrite, pH 3.5, for 5 h at 37 °C (9) or with 1 unit/ml PI-PLC from B. cereus in 25 mM HEPES, pH 7.4, for 2 h at 37 °C (36). Controls were done by incubating [3H]GPI with buffer alone. Reaction was terminated by the addition of chloroform/methanol (1:2), and the amount of radioactivity released in the aqueous phase after lipid extraction was determined. Results were expressed as the percentage of recovered radioactivity. Hydrolysis of purified [3H]GPI from WT FDC-P1 cells by mammalian PLC-gamma 2 was determined by incubation of Epo-activated PLC-gamma 2 from WT FDC-P1 cells bound on 2.5 mg of protein G beads or with PLC-gamma 2 from FDC-P1 ZERO obtained from a PLC-gamma 2 immunoprecipitation with 15 × 106 cells, in 250 µl of HEPES 25 mM, pH 7.4, for 2 h at 37 °C. Control was done by incubation of [3H]GPI with 2.5 mg of protein G beads in 250 µl of HEPES 25 mM, pH 7.4, for 2 h at 37 °C. Lipids were extracted with the same protocol as above. Then, [3H]GPI contained in the organic phase was reanalyzed by HPTLC and quantitated on Berthold analyzer before fluorography. IPG contained in the aqueous phase was quantitated as described previously (13, 21).

Determination of 2,5-Anhydromannitol-- A sample of presumed GPI labeled with [3H]glucosamine from WT Epo-R FDC-P1 cells recovered after the basic thin layer chromatography was hydrolyzed with nitrous acid. Then the deaminated glycan was reduced with sodium borotritide and subjected to solvolysis in 0.5 M methanolic HCl for 12 h at 80 °C as described previously (37). Samples were analyzed on Silica Gel 60 HPTLC plates developed for 10 cm in 1-propanol/acetone/water (9:6:5, v/v) (38) and were scanned on a Berthold analyzer. 2,5-[3H]Anhydromannitol control was prepared by treating [3H]glucosamine as above.

Immunoprecipitations and Immunoblottings-- Starved FDC-P1 cells expressing the WT and mutant Epo-R were incubated with or without Epo (5 units/ml) for 1-10 min at 37 °C. Cells were washed once with phosphate-buffered saline and solubilized at 2 × 107 cells/ml with 1% Brij 98 in solubilized buffer (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM Na2VO4, pH 7.4). Immunoprecipitations were done as described previously (5) with either anti-PLC-gamma 2 or anti-JAK2 antibodies. Following SDS-polyacrylamide gel electrophoresis using 7.5% polyacrylamide gels, proteins were electrophoretically transferred to protean nitrocellulose membrane. Blots were blocked, incubated with anti-PY antibodies and then with horseradish peroxidase-conjugated second antibody before adding ECL substrate solution and exposing to Kodak X-Omat film. When necessary, blots were stripped by incubating the membrane for 30 min at 55 °C in 62.5 mM Tris-HCl, pH 6.7, 100 mM beta -mercaptoethanol, 2% SDS. Then the blot was washed twice with 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20 and reprobed as described previously.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Evidence for Glycosylphosphatidylinositol in Epo-R-transfected FDC-P1 Cells-- GPI identification was done with cells metabolically labeled for 20 h with [3H]ethanolamine, a radiolabeled precursor of GPI. Polar lipids were then extracted and resolved by sequential acid/base thin layer chromatography (TLC) or by HPTLC. During the first acid TLC, GPI did not migrate and was clearly separated from phosphatidylethanolamine which migrated at 9 cm (not shown). The material around the origin (2 cm) was recovered and analyzed on a second TLC or on HPTLC which was run in an alkaline solvant system. As shown in Fig. 2, A-C, a single peak of [3H]glycolipidic fraction was recovered between phosphatidylcholine (PC) and phosphatidylinositol monophosphate (PIP). The same fraction was also labeled in extracts from WT Epo-R FDC-P1 cells incubated with [3H]inositol or [3H]glucosamine instead of [3H]ethanolamine (not shown).


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 2.   Identification of GPI from FDC-P1 cells transfected with the wild-type Epo-R, chromatographic isolation of GPI. After cell labeling for 20 h with [3H]ethanolamine (1.5 µCi/ml), total cellular lipids were extracted, and GPI was purified by sequential TLC on Silica Gel 60 (A) or on HPTLC (B and C) as described under "Experimental Procedures." Radioactivity was detected by counting 1-cm bands of TLC by scintillation (A), Berthold analysis (B), or fluorographic analysis (C). O, origin; F, solvent front. The migration patterns of known phospholipids are indicated: PIP, phosphatidylinositol monophosphate; PC, phosphatidylcholine. Presented data correspond to one experiment out of six others.

Characterization of GPI was confirmed by testing the sensitivity of the radiolabeled product to several GPI-hydrolyzing conditions. The recovered [3H]ethanolamine glycolipid fraction was first treated with nitrous acid that hydrolyzes the glycosidic bond between inositol and glucosamine. After deamination by nitrous acid, about 65% of the labeled material was recovered in the aqueous phase, and 10.5% of the radioactivity was recovered in the aqueous phase in control incubations. Moreover, we have shown 2,5-[3H]anhydromannitol production after having deaminated/reduced and methanolyzed the recovered [3H]glucosamine glycolipid fraction (Fig. 3, A-C). We further investigated the cleavage of the purified recovered 3H-labeled lipidic peak from WT Epo receptor-transfected FDC-P1 cells by PI-specific phospholipase C (PI-PLC) from B. cereus. After treatment, about 21% of the labeled material was recovered in the aqueous phase versus control 5%. These values are in good agreement with previously published results showing the sensitivity of GPI from various tissues to B. cereus PI-PLC (24, 39). Altogether, our results show that the lipidic products extracted from FDC-P1 WT Epo receptor-transfected cells and migrating between PIP and PC corresponded to GPI.


View larger version (8K):
[in this window]
[in a new window]
  		Fig. 3.   Determination of 2,5-anhydromannitol (AHM). A sample of recovered glycolipidic fraction (10,000 cpm) labeled with [3H]glucosamine was hydrolyzed with nitrous acid and reduced with sodium borotritide and subjected to 0.5 M methanolic HCl solvolysis. Control was prepared by treating a [3H]glucosamine (G) sample as above. Samples were analyzed on HPTLC plates developed for 10 cm as described under "Experimental Procedures" and scanned on Berthold analyzer: A, control with 2,5-[3H]AHM; B, [3H]AHM recovered after treatment of the glycolipidic fraction. C, fluorographic analysis: lane 1, control with 2,5-[3H]AHM; lane 2, [3H]AHM recovered after treatment of the glycolipidic fraction.

Epo-induced GPI Hydrolysis in Epo-R-transfected FDC-P1 Cells-- GPI hydrolysis was assessed by measuring both GPI or inositol phosphate glycan (IPG) levels (its hydrolysis product) from cells metabolically labeled with [3H]ethanolamine. Epo (5 units/ml) induced a rapid and transient GPI hydrolysis with a parallel IPG release within 1 min in FDC-P1 cells transfected with WT Epo-R. Then the IPG level rapidly decreased and returned to control values after 30 min of Epo exposure. No GPI hydrolysis was detected after Epo stimulation of non-transfected FDC-P1 cells (Fig. 4).


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4.   Time course of Epo-induced GPI hydrolysis and IPG. Wild-type (WT) or non-transfected (NT) FDC-P1 cells (20 × 106) labeled with [3H]ethanolamine (1.5 µCi/ml) for 20 h were deprived of growth factor and stimulated with Epo (5 units/ml). GPI () and IPG (black-diamond ) levels from WT-FDC-P1 cells, GPI (black-square), and IPG (black-triangle) levels from NT-FDC-P1 cells were measured at different times as described under "Experimental Procedures." Results are expressed as percent of the zero time value and are the mean of three separate experiments. 100% represents 2200 ± 410 dpm for IPG and 14,600 ± 660 dpm for GPI from WT-FDC-P1 cells and 2880 ± 230 dpm for IPG and 13,820 ± 420 dpm for GPI from NT-FDC-P1 cells.

Epo Induced the Tyrosine Phosphorylation of PLC-gamma 2 in Epo-R-transfected FDC-P1 Cells-- To assay the possible involvement of PLC-gamma 2 in Epo-induced GPI hydrolysis, we first investigated its tyrosine phosphorylation in WT Epo-R FDC-P1 cells upon Epo stimulation. As shown in Fig. 5A, Epo induced the tyrosine phosphorylation of a 142-kDa protein immunoprecipitated with anti-PLC-gamma 2 antibodies. This effect was maximal after 1-2 min of Epo stimulation and then decreased after 5 min of stimulation. Reprobing the blot with anti-PLC-gamma 2 antibodies confirmed that the 142-kDa protein was indeed PLC-gamma 2. Epo-induced PLC-gamma 2 tyrosine phosphorylation was dose-dependent as shown in Fig. 5B and the Epo effect was maximal at 0.1 units/ml.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 5.   Time and dose dependence of PLC-gamma 2 tyrosine phosphorylation induced by Epo. Growth factor-deprived WT FDC-P1 cells were stimulated either with Epo (5 units/ml) for 0-10 min (A) as indicated or for 1 min (B) with different Epo concentrations as indicated. Cells lysates were immunoprecipitated (IP) with anti-PLC-gamma 2 antibodies, and immunoprecipitated proteins were immunoblotted with anti-phosphotyrosine antibodies (PY). The blot was then stripped and reprobed with anti-PLC-gamma 2 antibodies.

Tyrosine Residues of the Epo-R Are Required for Epo-induced PLC-gamma 2 Tyrosine Phosphorylation-- In order to know whether tyrosine residues of the Epo-R play a significant role in Epo-induced PLC-gamma 2 tyrosine phosphorylation, we used interleukin-3-dependent FDC-P1 cells transfected with the wild-type (WT) Epo-R and with Epo-R devoid of tyrosine residue (ZERO) (Fig. 1). Then, cells were stimulated for 1 min with Epo 5 units/ml. Cellular extracts were immunoprecipitated with anti-PLC-gamma 2 antibodies and analyzed by Western blotting. As shown in Fig. 6, in contrast to FDC-P1 cells expressing WT Epo-R, Epo did not induce the tyrosine phosphorylation of PLC-gamma 2 in FDC-P1 cells ZERO, suggesting that the tyrosine residues of the intracellular domain of the Epo-R were required for Epo-induced tyrosine phosphorylation of PLC-gamma 2. Reprobing the blot with anti-PLC-gamma 2 antibodies showed that the same amounts of PLC-gamma 2 had been immunoprecipitated from each sample. Moreover, JAK2 immunoprecipitations carried on the same cellular extracts followed by an anti-phosphotyrosine blot showed that these cells were stimulated by Epo.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 6.   Tyrosine residues of the intracellular domain of the Epo receptor are required for Epo-induced PLC-gamma 2 tyrosine phosphorylation. FDC-P1 cells expressing either the wild-type Epo receptor (WT) or the mutant receptor (ZERO) devoid of tyrosine residues in its intracellular domain were deprived of growth factor for 4 h and then stimulated for 1 min with 5 units/ml of Epo (+) or with vehicle alone (-); cells lysates were immunoprecipitated (IP) with anti-PLC-gamma 2 antibodies, and immunoprecipitated proteins were immunoblotted with anti-phosphotyrosine antibodies (PY). The blot was stripped and reprobed with anti-PLC-gamma 2 antibodies. A control of Epo stimulation was done on the same cellular extracts using JAK2 immunoprecipitation followed by an anti-phosphotyrosine blot.

PLC-gamma 2 immunoprecipitations from FDC-P1 cells expressing various Epo-R mutants were achieved after Epo stimulation. As shown in Fig. 7, PLC-gamma 2 tyrosine phosphorylation was found to occur in mutants Y1, F1Y2, F1Y5-8, and in Y1-2F3-4Y5-8 upon Epo stimulation. It was more important in Y1-2F3-4Y5-8 FDC-P1 cells than in WT FDC-P1 cells. In F1Y3-4 and Y1-6 FDC-P1 cells, an inhibition of PLC-gamma 2 tyrosine phosphorylation was seen after Epo stimulation. It was probably due to the presence of Tyr428-431 which inhibited PLC-gamma 2 phosphorylation. This hypothesis was confirmed by the enhanced PLC-gamma 2 activation observed in Epo-stimulated Y1-2F3-4Y5-8 FDC-P1 cells. Altogether, our results suggest that Tyr343, Tyr401, and Tyr464 and/or Tyr479 are involved in PLC-gamma 2 activation, whereas Tyr429 and/or Tyr431 reduced this PLC-gamma 2 activation.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 7.   Epo-induced tyrosine phosphorylation of PLC-gamma 2 in FDC-P1 cells transfected with various Epo-R mutants. FDC-P1 cells expressing either the wild-type Epo receptor (WT) or mutants Epo-R were deprived of growth factor for 4 h and then stimulated for 1 min with 5 units/ml of Epo (+) or with vehicle alone (-). Cells lysates were immunoprecipitated (IP) with anti-PLC-gamma 2 antibodies, and immunoprecipitated proteins were analyzed by Western blotting with anti-phosphotyrosine (PY) antibodies. The blot was then stripped and reprobed with anti-PLC-gamma 2 antibodies.

Correlation between Epo-induced GPI Hydrolysis and PLC-gamma 2 Tyrosine Phosphorylation-- Treatment of recovered [3H]GPI with Epo-activated PLC-gamma 2 bound on protein G beads from immunoprecipitates of WT or ZERO-FDC-P1 cells resulted in an hydrolysis of about 50.2 and 9.8%, respectively (Fig. 8A). Analysis of the resultant products showed a greater IPG content released in the aqueous phase in samples treated with Epo-activated PLC-gamma 2 from WT FDC-P1 cells than from ZERO FDC-P1 cells (Fig. 8A). To the contrary, analysis of [3H]GPI remaining in the organic phase is greater in sample hydrolyzed with Epo-activated PLC-gamma 2 from ZERO FDC-P1 than from WT FDC-P1 cells (Fig. 8, B and C). This demonstrated that PLC-gamma 2 tyrosine phosphorylation is required for GPI hydrolysis. Moreover, as described previously, Epo induced a rapid IPG release within 1 min in FDC-P1 cells transfected with WT Epo-R, and no change of IPG levels was observed in FDC-P1 cells ZERO after Epo stimulation (Fig. 9). IPG levels were also determined upon Epo stimulation (5 units/ml, 1 min) in metabolically labeled FDC-P1 cells expressing various Epo-R mutants. These experiments show an excellent correlation between Epo-induced PLC-gamma 2 tyrosine phosphorylation and Epo-induced GPI hydrolysis. Indeed, after Epo stimulation, IPG levels were increased in Y1 and in F1Y2 mutants which only retains a single tyrosine at positions 343 and 401, respectively. These cells differ from FDC-P1 ZERO by only one tyrosine. Nevertheless, IPG level in Y1 or Y2 mutants was about half the level obtained in WT-Epo-R FDC-P1 transfected cells. IPG level was greatly increased after Epo stimulation in F1Y5-8 mutant, but IPG increase was also lower than in WT-Epo-R FDC-P1 transfected cells. In Y1-2F3-4Y5-8, IPG level obtained after Epo stimulation was greater than in WT-Epo-R FDC-P1-transfected cells. In F1Y3-4 and Y1-6 mutants, Epo induced an inhibition of IPG basal level (Fig. 9).


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 8.   Correlation between Epo-induced GPI hydrolysis and PLC-gamma 2 activation. A, [3H]GPI from WT FDC-P1 cells recovered after TLC was incubated for 2 h at 37 °C with Epo-activated PLC-gamma 2 from WT FDC-P1 cells or PLC-gamma 2 from Epo-R mutant ZERO as described under "Experimental Procedures." Control reaction was obtained with protein G beads in buffer alone. Values were corrected by subtraction of values obtained from control incubations in the absence of PLC-gamma 2 (14%). Results are presented as the means of triplicate experiments and are expressed as the percentage of the initial label recovered in the aqueous phase after treatment and extraction. Analysis of hydrolysis products was done on one representative experiment; IPG was measured in the aqueous phase (inset), and [3H]GPI remaining in the organic phase was quantitated by Berthold analysis (B) or by fluorographic analysis (C). O, origin; F, solvent front; PIP, phosphatidylinositol monophosphate; PC, phosphatidylcholine.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 9.   Epo-induced GPI hydrolysis in FDC-P1 cells transfected with various Epo-R mutants. FDC-P1 cells expressing either the wild-type Epo receptor or Epo-R mutants were labeled with [3H]ethanolamine (1.5 µCi/ml) for 20 h, deprived of growth factor for 4 h, and then stimulated for 1 min with 5 units/ml Epo (+) or with vehicle alone (-). IPG release was determined as described under "Experimental Procedures" in WT cells and Epo-R mutants. Data are the means of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our results show that FDC-P1 cells contain GPI molecules that are hydrolyzed to produce IPG after Epo stimulation. After TLC or HPTLC analysis, GPI migrated as a single peak between PC and PIP as described previously in Epo-sensitive cells (21) and in other cells (14, 37, 36). The material of this peak exhibited all the characteristics of GPI. Indeed, it could be labeled with [3H]inositol and [3H]glucosamine in addition to [3H]ethanolamine. Moreover, the GPI structure of this lipid was confirmed by its partial sensitivity to PI-PLC from B. cereus and nitrous deamination of the free amino group on glucosamine. Presence of glucosamine in 3H-recovered glycolipidic fraction was also confirmed by 2,5-anhydromannitol obtained after deamination/reduction and methanolysis of this molecule. Altogether these results indicate that the labeled glycolipid fraction corresponds to GPI. It has been previously shown that GPI displays various degrees of sensitivity to bacterial PI-PLCs cleavage (14, 19, 23, 24, 36, 39). Epo stimulation of Epo receptor-transfected FDC-P1 cells metabolically labeled with [3H]glucosamine induced the same level of GPI hydrolysis with release of water-soluble IPG forms. In contrast to GPI molecules involved in insulin signal transduction in H35 hepatoma cells which does not contain ethanolamine (14, 40), our results show that GPI molecules containing ethanolamine are involved in Epo signal transduction.

Bacterial PI-PLCs can partially mimic the effects of the extracellular ligand on GPI through the generation of diacylglycerol and IPG (13, 41, 42), suggesting that the formation of IPG from GPI is due to the activation of a phospholipase C. A GPI-specific PLC has been purified and cloned from T. brucei (43) and peanuts (44). It is able to hydrolyze GPI-anchored proteins and phosphatidylinositol. However, this enzyme is not active on free GPI phospholipids (45). A mammalian GPI-PLC has been partially purified from rat liver membranes (26) but has not been cloned. The presence of two different GPI-PLC activities has also been reported in brain membranes (46). Our results strongly suggest that Epo induced the hydrolysis of GPI through the activation of PLC-gamma 2. Indeed, PLC-gamma 2 immunoprecipitated from Epo-stimulated FDC-P1 cells was able to hydrolyze GPI molecules purified from these cells. The time course of Epo-induced PLC-gamma 2 tyrosine phosphorylation displays a good parallelism with the kinetics of Epo-induced GPI hydrolysis. Moreover, we observed a full correlation between the ability for mutated Epo receptors to activate PLC-gamma 2 and to induce IPG release. PLC-gamma 2 is expressed mainly in hematopoietic cells (47). In FDC-P1 cells, macrophage-colony-stimulating factor induces activation of PLC-gamma 2 and its tyrosine phosphorylation (34). Here, we observed that Epo stimulation of WT FDC-P1 cells induced a rapid tyrosine phosphorylation and dephosphorylation of PLC-gamma 2 since maximal tyrosine phosphorylation was detected between 1 and 2 min and decreased after this time. Although Epo-induced PLC-gamma 2 has not been previously reported, it has been shown that Epo activates PLC-gamma 1 in the UT-7 human cell line (33). The mechanism of PLC-gamma 1 activation by Epo was not reported. Our results indicate that the tyrosine residues of the Epo receptor are involved in the activation of PLC-gamma 2. Indeed, Epo receptors devoid of tyrosine residue on their intracellular domain did not activate PLC-gamma 2. In contrast, Epo induced the activation of PLC-gamma 2 in FDC-P1 cells expressing Epo receptors with either the first (Tyr343) or second tyrosine (Tyr401) residue albeit to a reduced level compared with cells expressing normal Epo receptors. Nevertheless, our results indicate that the main activation site for PLC-gamma 2 is located in the C-terminal part of the receptor, suggesting that the seventh or eighth tyrosine residue could be involved in this activation. Yet, we could not show that PLC-gamma 2 is associated with the activated Epo-R and coimmunoprecipitate with it as for PLC-gamma 1 in UT7/Epo cells (33). This was probably due to the rapid dissociation of the SH2 domains of PLC-gamma 2 from the phosphorylated tyrosine residues of the Epo receptor (48). Previous results have indicated that an intact tyrosine kinase activity is required for GPI hydrolysis in response to growth factors in Chinese hamster ovary cells carrying normal human insulin receptors. These cells hydrolyze up to 70% of their GPI within 2 min after the addition of 0.1 nM insulin, whereas cells expressing a mutant cDNA (Lys-1018 to Ala) that encodes a receptor lacking kinase activity (49) hydrolyzes only 20-30% in response to insulin (24). More recently, Clemente et al. (23) had indicated that tyrosine kinase inhibitors partially block GPI hydrolysis in parallel to the inhibition of both EGF receptor autophosphorylation and EGF-induced cell proliferation.

Our results also indicate that the tyrosine residues Tyr429 and/or Tyr431 are involved in deactivation of PLC-gamma 2 phosphorylation and in GPI hydrolysis inhibition. Indeed, Epo-induced PLC-gamma 2 tyrosine phosphorylation and GPI hydrolysis in mutants F1Y3-4 are lower than in controls without Epo but are greater in mutants Y1-2F3-4Y5-8 (deprived of Tyr429 and Tyr431) than in WT FDC-P1 cells. Then tyrosines Tyr429 and/or Tyr431 appear to be negative regulators of GPI hydrolysis. The Tyr429 was identified as the protein tyrosine phosphatase SHP1 in the cytoplasmic domain of the Epo-R (50). Thus, our results suggest that PLC-gamma 2 could be a substrate for Epo-activated SHP1.

The levels of cell surface expression of Epo-R have been already published for the cell lines used in this study (35) except for the mutant Y1-2F3-4Y5-8 which expressed 880 ± 50 Epo receptors. Most Epo-R mutants used in our experiments have been previously shown to be able to mediate Epo-induced Stat5 activation (35). Moreover, the ZERO Epo-R mutant which did not activate Stat5 (35) mediates Epo-induced JAK2 activation (Fig. 6). These results show that all Epo-R mutants used in our experiments were activated by Epo. Although the levels of the cell surface expression are not identical, it should be noted that in WT FDC-P1 cells which expressed about 2100 Epo receptors or in Y1-2F3-4 Y5-8, we could detect a good level of phosphorylation of PLC-gamma 2 and GPI hydrolysis, whereas in mutant ZERO (without tyrosine residue) or in F1Y3-4 which expressed about 5700 and 7700 Epo receptors, respectively, we could not observe any PLC-gamma 2 activation nor any GPI hydrolysis. From our results, we conclude that the levels of both Epo receptors are not correlated to GPI hydrolysis.

A low level of PLC-gamma 2 tyrosine phosphorylation in immunoprecipitates of control cells was often observed. Nevertheless, no tyrosine phosphorylation of the Epo receptor was observed in these cells (not shown). This low level of PLC-gamma 2 could be attributed to unidentified molecules present in the fetal calf serum required to maintain cell survival during Epo starvation.

The GPI/IPG pathway in Epo signal transduction has already been described in rat erythroid progenitor cells. Erythropoietin-stimulation of these cells increases GPI hydrolysis with a parallel increase in IPG levels, and purified erythroid rat IPG partially mimicked Epo-proliferative effects on erythroid colonies (21). We have also shown that IPG induced Raf-1 and mitogen-activated protein kinase (p44 form) activation, and we also suggested that protein kinase C could be involved in this activation (51). Data presented here suggest a direct link between Epo receptor tyrosine phosphorylation leading to activation of PLC-gamma 2 and GPI hydrolysis and provide complementary information on the GPI/IPG pathway in Epo-proliferative effects.

    ACKNOWLEDGEMENT

We thanks Marie-Line Sowa for excellent technical work.

    FOOTNOTES

* This work was supported by grants from the Ligue Nationale Contre le Cancer, Comité de la Marne, and Comité de l'Aube.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Fax: 33-03.26.91.32.79.

    ABBREVIATIONS

The abbreviations used are: Epo-R, erythropoietin receptor; alpha -MEM, alpha -minimum essential medium; GPI, glycosylphosphatidylinositol; SH2, Src homology domain 2; IPG, inositol phosphoglycan; EGF, epidermal growth factor; PLC, phospholipase C; PI-PLC, phosphatidylinositol-phospholipase C; WT, wild type; HPTLC, high performance thin layer chromatography; AHM, 2,5-anhydromannitol; PIP, phosphatidylinositol monophosphate; PC, phosphatidylcholine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Krantz, S. B. (1991) Blood 77, 419-434[Free Full Text]
2. Koury, M. J., and Bondurant, M. C. (1992) Eur. J. Biochem. 210, 649-663[Medline] [Order article via Infotrieve]
3. Miura, O., D'Andrea, A., Kabat, D., and Ihle, J. N. (1991) Mol. Cell. Biol. 11, 4895-4902[Abstract/Free Full Text]
4. Quelle, F. W., and Wojchowski, D. M. (1991) J. Biol. Chem. 266, 609-614[Abstract/Free Full Text]
5. Dusanter-Fourt, I., Casadevall, N., Lacombe, C., Muller, O., Billat, C., Fischer, S., and Mayeux, P. (1992) J. Biol. Chem. 267, 10670-10675[Abstract/Free Full Text]
6. Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. N. (1993) Cell 74, 227-236[CrossRef][Medline] [Order article via Infotrieve]
7. Miura, O., Nakamura, N., Quelle, F. W., Witthuhn, B. A., Ihle, J. N., and Aoki, N. (1994) Blood 84, 1501-1507[Abstract/Free Full Text]
8. Damen, J. E., and Krystal, G. (1996) Exp. Hematol. 24, 1455-1459[Medline] [Order article via Infotrieve]
9. Ferguson, M. A., and Williams, A. F. (1988) Annu. Rev. Biochem. 57, 285-320[CrossRef][Medline] [Order article via Infotrieve]
10. Gaulton, G. N., and Pratt, J. C. (1994) Semin. Immunol. 6, 97-104[CrossRef][Medline] [Order article via Infotrieve]
11. Thomas, J. R., Dwek, R. A., and Rademacher, T. W. (1990) Biochemistry 29, 5413-5422[CrossRef][Medline] [Order article via Infotrieve]
12. Jones, D. R., and Varela-Nieto, I. (1998) Int. J. Biochem. Cell Biol. 30, 313-326[CrossRef][Medline] [Order article via Infotrieve]
13. Saltiel, A. R., and Cuatrecasas, P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 5793-5797[Abstract/Free Full Text]
14. Mato, J. M., Kelly, K. L., Abler, A., and Jarett, L. (1987) J. Biol. Chem. 262, 2131-2137[Abstract/Free Full Text]
15. Farese, R. V., Nair, G. P., Standaert, M. L., and Cooper, D. R. (1988) Biochem. Biophys. Res. Commun. 156, 1346-1352[CrossRef][Medline] [Order article via Infotrieve]
16. Kojima, I., Kitaoka, M., and Ogata, E. (1990) J. Biol. Chem. 265, 16846-16850[Abstract/Free Full Text]
17. Chan, B. L., Chao, M. V., and Saltiel, A. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1756-1760[Abstract/Free Full Text]
18. Represa, J., Avila, M. A., Miner, C., Giraldez, F., Romero, G., Clemente, R., Mato, J. M., and Varela-Nieto, I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8016-8019[Abstract/Free Full Text]
19. Merida, I., Pratt, J. C., and Gaulton, G. N. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9421-9425[Abstract/Free Full Text]
20. Martiny, L., Antonicelli, F., Thuilliez, B., Lambert, B., Jacquemin, C., and Haye, B. (1990) Cell. Signal. 2, 21-27[CrossRef][Medline] [Order article via Infotrieve]
21. Devemy, E., Billat, C., Sartelet, H., Martiny, L., and Haye, B. (1994) Cell. Signal. 6, 523-529[CrossRef][Medline] [Order article via Infotrieve]
22. Varela-Nieto, I., Leon, Y., and Caro, H. N. (1996) Comp. Biochem. Physiol. 115, 223-241[CrossRef]
23. Clemente, R., Jones, D. R., Ochoa, P., Romero, G., Mato, J. M., and Varela-Nieto, I. (1995) Cell. Signal. 7, 411-421[CrossRef][Medline] [Order article via Infotrieve]
24. Villalba, M., Alvarez, J. F., Russell, D. S., Mato, J. M., and Rosen, O. M. (1990) Growth Factors 2, 91-97[Medline] [Order article via Infotrieve]
25. Suzuki, S., Taneda, Y., Hirai, S., Yamamoto-Honda, R., and Toyota, T. (1992) Diabetes 41, 1373-1379[Abstract]
26. Fox, J. A., Soliz, N. M., and Saltiel, A. R. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 2663-2667[Abstract/Free Full Text]
27. Hereld, D., Krakow, J. L., Bangs, J. D., Hart, G. W., and Englund, P. T. (1986) J. Biol. Chem. 261, 13813-13819[Abstract/Free Full Text]
28. Kuppe, A., Evans, L. M., McMillen, D. A., and Griffith, O. H. (1989) J. Bacteriol. 171, 6077-6083[Abstract/Free Full Text]
29. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302[CrossRef][Medline] [Order article via Infotrieve]
30. Pawson, T., and Gish, G. D. (1992) Cell 71, 359-362[CrossRef][Medline] [Order article via Infotrieve]
31. Schlessinger, J. (1994) Curr. Opin. Genet. & Dev. 4, 25-30[CrossRef][Medline] [Order article via Infotrieve]
32. Mason-Garcia, M., Clejan, S., Tou, J.-S., and Beckman, B. S. (1992) Am. J. Physiol. 262, C1197-C1203[Abstract/Free Full Text]
33. Ren, H.-Y., Komatsu, N., Shimizu, R., Okada, K., and Miura, Y. (1994) J. Biol. Chem. 269, 19633-19638[Abstract/Free Full Text]
34. Bourette, R. P., Myles, G. M., Choi, J.-L., and Rohrschneider, L. R. (1997) EMBO J. 16, 5880-5893[CrossRef][Medline] [Order article via Infotrieve]
35. Gobert, S., Chretien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt, I., Groner, B., Lacombe, C., Gisselbrecht, S., and Mayeux, P. (1996) EMBO J. 15, 2434-2441[Medline] [Order article via Infotrieve]
36. Gaulton, G. N., Kelly, K. L., Pawlowski, J., Mato, J. M., and Jarett, L. (1988) Cell 53, 963-970[CrossRef][Medline] [Order article via Infotrieve]
37. Ralton, J. E., and McConville, M. J. (1998) J. Biol. Chem. 273, 4245-4257[Abstract/Free Full Text]
38. Schneider, P., Ralton, J. E., McConville, M. J., and Fergusson, M. A. J. (1993) Anal. Biochem. 210, 106-112[CrossRef][Medline] [Order article via Infotrieve]
39. Eardley, D. D., and Koshland, M. E. (1991) Science 251, 78-81[Abstract/Free Full Text]
40. Mato, J. M., Kelly, K. L., Abler, A., Jarett, L., Corkey, B. E., Cashel, J. A., and Zopf, D. (1987) Biochem. Biophys. Res. Commun. 146, 764-770[CrossRef][Medline] [Order article via Infotrieve]
41. Macaulay, S. L., and Larkins, R. G. (1990) Cell. Signal. 2, 9-19[CrossRef][Medline] [Order article via Infotrieve]
42. Vila, M. C., Milligan, G., Standaert, M. L., and Farese, R. V. (1990) Biochemistry 29, 8735-8740[CrossRef][Medline] [Order article via Infotrieve]
43. Bulow, R., and Overath, P. (1986) J. Biol. Chem. 261, 11918-11923[Abstract/Free Full Text]
44. Bütikofer, P., and Brodbeck, U. (1993) J. Biol. Chem. 268, 17794-17802[Abstract/Free Full Text]
45. Jones, D. R., Avila, M. A., Sanz, C., and Varela-Nieto, I. (1997) Biochem. Biophys. Res. Commun. 233, 432-437[CrossRef][Medline] [Order article via Infotrieve]
46. Fouchier, F., Baltz, T., and Rougon, G. (1990) Biochem. J. 269, 321-327[Medline] [Order article via Infotrieve]
47. Noh, D.-Y., Shin, S. H., and Rhee, S. G. (1995) Biochim. Biophys. Acta 1242, 99-114[Medline] [Order article via Infotrieve]
48. Rhee, S. G. (1991) Trends Biochem. Sci. 16, 297-301[CrossRef][Medline] [Order article via Infotrieve]
49. Chou, C. K., Dull, T. J., Russell, D. S., Gherzi, R., Lebwohl, D., Ullrich, A., and Rosen, O. M. (1987) J. Biol. Chem. 262, 1842-1847[Abstract/Free Full Text]
50. Klingmüller, U., Lorenz, U., Cantley, L. C., Neel, B. G., and Lodish, H. F. (1995) Cell 80, 729-738[CrossRef][Medline] [Order article via Infotrieve]
51. Devemy, E., Billat, C., and Haye, B. (1997) Cell. Signal. 9, 41-46[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Q. Tong, I. Hirschler-Laszkiewicz, W. Zhang, K. Conrad, D. W. Neagley, D. L. Barber, J. Y. Cheung, and B. A. Miller
TRPC3 Is the Erythropoietin-regulated Calcium Channel in Human Erythroid Cells
J. Biol. Chem., April 18, 2008; 283(16): 10385 - 10395.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Um and H. F. Lodish
Antiapoptotic Effects of Erythropoietin in Differentiated Neuroblastoma SH-SY5Y Cells Require Activation of Both the STAT5 and AKT Signaling Pathways
J. Biol. Chem., March 3, 2006; 281(9): 5648 - 5656.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Montoye, I. Lemmens, D. Catteeuw, S. Eyckerman, and J. Tavernier
A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach
Blood, June 1, 2005; 105(11): 4264 - 4271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
Q. Tong, X. Chu, J. Y. Cheung, K. Conrad, R. Stahl, D. L. Barber, G. Mignery, and B. A. Miller
Erythropoietin-modulated calcium influx through TRPC2 is mediated by phospholipase C{gamma} and IP3R
Am J Physiol Cell Physiol, December 1, 2004; 287(6): C1667 - C1678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Haq, A. Halupa, B. K. Beattie, J. M. Mason, B. W. Zanke, and D. L. Barber
Regulation of Erythropoietin-induced STAT Serine Phosphorylation by Distinct Mitogen-activated Protein Kinases
J. Biol. Chem., May 3, 2002; 277(19): 17359 - 17366.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
M. Shirane, H. Sawa, Y. Kobayashi, T. Nakano, K. Kitajima, Y. Shinkai, K. Nagashima, and I. Negishi
Deficiency of phospholipase C-{gamma}1 impairs renal development and hematopoiesis
Development, December 15, 2001; 128(24): 5173 - 5180.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
G. Muller, C. Jung, S. Wied, S. Welte, H. Jordan, and W. Frick
Redistribution of Glycolipid Raft Domain Components Induces Insulin-Mimetic Signaling in Rat Adipocytes
Mol. Cell. Biol., July 15, 2001; 21(14): 4553 - 4567.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boudot, C.
Right arrow Articles by Billat, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boudot, C.
Right arrow Articles by Billat, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement